In Brief: Astra Merck/Lexin
Executive Summary
Astra Merck/Lexin: Companies collaborate on development work of Lexin's recombinant human protein LEX032 for treatment of acute pancreatitis. Under the agreement, Astra Merck will fund preclinical studies conducted at Wayne, Penn.-based Lexin. Astra Merck retains an option to obtain manufacturing and marketing rights, and a clinical development program will be negotiated if Astra Merck exercises this option...